{"id":"adalimumab-current-formulation","safety":{"commonSideEffects":[{"rate":"10%","effect":"Injection site reaction"},{"rate":"10%","effect":"Headache"},{"rate":"10%","effect":"Fatigue"},{"rate":"5%","effect":"Nausea"},{"rate":"5%","effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Adalimumab binds to tumor necrosis factor-alpha (TNF-alpha), preventing its interaction with cell surface TNF receptors and subsequent inflammatory response.","oneSentence":"Tumor necrosis factor-alpha inhibitor","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:20:50.128Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid Arthritis"},{"name":"Psoriatic Arthritis"},{"name":"Ankylosing Spondylitis"},{"name":"Crohn's Disease"},{"name":"Ulcerative Colitis"}]},"trialDetails":[{"nctId":"NCT03816397","phase":"PHASE4","title":"Adalimumab in JIA-associated Uveitis Stopping Trial","status":"COMPLETED","sponsor":"Nisha Acharya","startDate":"2020-03-15","conditions":"Uveitis, JIA","enrollment":87},{"nctId":"NCT02862574","phase":"PHASE2","title":"Andecaliximab as Add-On Therapy to a Tumor Necrosis Factor Inhibitor and Methotrexate Regimen in Adults With Moderately to Severely Active Rheumatoid Arthritis","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2016-12-15","conditions":"Rheumatoid Arthritis","enrollment":15},{"nctId":"NCT01712178","phase":"PHASE2","title":"A Study in Rheumatoid Arthritis (RA) Patients to Compare Two Formulations of Adalimumab for Pharmacokinetic, Pharmacodynamic and Safety","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2012-06","conditions":"Rheumatoid Arthritis","enrollment":100},{"nctId":"NCT01502423","phase":"PHASE2","title":"A Crossover Study of the Safety and Tolerability of Two Formulations of Adalimumab","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2012-01","conditions":"Rheumatoid Arthritis","enrollment":61},{"nctId":"NCT01561313","phase":"PHASE2","title":"Crossover Study of Safety and Tolerability of Two Formulations of Adalimumab.","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2012-03","conditions":"Rheumatoid Arthritis","enrollment":64}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Humira"],"phase":"phase_2","status":"active","brandName":"Adalimumab, current formulation","genericName":"Adalimumab, current formulation","companyName":"AbbVie (prior sponsor, Abbott)","companyId":"abbvie-prior-sponsor-abbott","modality":"Biologic","firstApprovalDate":"","aiSummary":"Tumor necrosis factor-alpha inhibitor Used for Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}